BPC-157
Also known as: Body Protection Compound 157, PL 14736, Bepecin
BPC-157 (also called Body Protection Compound 157 or PL 14736) is a research peptide in the Wound Healing / Cytoprotective class. Preclinical work reports angiogenesis, nitric-oxide modulation, and growth-factor (VEGFR2, FAK) signaling that may support tendon, muscle, and gut mucosal healing in animals.
For research use only.
Key Facts
- CAS
- 137525-51-0
- Molecular Weight (MW)
- 1419.5 g/mol
- Half-life
- ~30 minutes to 4 hours
- FDA status
- Not Approved
- Evidence level
- Insufficient Evidence
- Human dose established
- No
- Administration Route
- Not established in humans
- Frequency
- Not established in humans
- Last updated
- Sep 26, 2026
- Reviewed
- Aug 30, 2026
- Targets
- VEGFR2 / FAK pathwaysNitric oxide systemGI mucosa
Vendor price snapshot
Each vendor counts once, at the median price per mg of its own listings; the typical range is the middle half of vendors. From public vendor listings collected between Dec 2025 and Sep 2026, so confirm the live price on the vendor site. Peptide Library does not sell peptides.
- Vendors listing this peptide
- 38
- Listed offers
- 103
- Median price per mg
- $7.47/mg
- Typical $6.00โ$10.37/mg
Research summary
Synthetic gastric pentadecapeptide widely sold as a research chemical for tissue-repair models. Not FDA-approved; FDA has flagged it for compounding risk. WADA prohibits BPC-157 under S0.
Peptide Library's BPC-157 profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
BPC-157 dosage: no established human dose
BPC-157 has no established human dosage. No completed human trial has published dosing results. Two registered trials disclose a regimen: a phase 1 study of an oral tablet formulation at 1, 3 or 6 mg, whose status is listed as unknown and which has published no results, and a phase 2 hamstring-injury trial that is still recruiting and does not disclose its dose. Neither supports the subcutaneous microgram protocols published elsewhere.
No established human dosage.
Human clinical evidence: None identified.
Preclinical research: BPC-157 has roughly 217 indexed publications, overwhelmingly rodent work on gastrointestinal, tendon, ligament and wound healing, and a large share originates from a small number of collaborating research groups. That literature establishes activity in those animal models. It does not establish a human dose, and animal dosing is not converted into a human equivalent anywhere on this page.
Animal dosing is not converted into a human dose anywhere on this page. Where research figures appear below, they are reported as studied, not recommended.
| Human dosing established | No |
|---|---|
| Route | Not established in humans |
| Evidence level | Insufficient Evidence |
| Last reviewed | 2026-09-05 |
Human research reported
Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| NCT02637284 โ phase 1, status unknown, no resultsClinical trial ยท Phase 1 safety and PK trial; registry status "unknown", no results posted | Healthy volunteers (n=42) | 1 mg, 3 mg or 6 mg as oral tablets (Bepecin / PCO-02), single ascending dose | Oral | Single dose (phase 1a) | Single dose, then a repeat-dose phase | Safety and pharmacokinetics | NCT02637284 โ PCO-02 Safety and Pharmacokinetics Trial |
| NCT07437547 โ phase 2, recruiting, no resultsClinical trial ยท Registered phase 2 randomised placebo-controlled trial, recruiting | Adults with acute hamstring muscle strain (planned n=120) | Not disclosed | Subcutaneous | Once daily | 14 days | Hamstring muscle strain repair | NCT07437547 โ BPC 157 for Acute Hamstring Muscle Strain Repair |
Preclinical and analog research
Not human dosing evidence. Listed for completeness and never extrapolated to a human dose.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| Preclinical โ literature and patent reviewPreclinical ยท Preclinical literature and patent review | Rodent models | Model-specific; not convertible to a human dose | Varies by model | โ | โ | Gastrointestinal, tendon, ligament and wound healing | Multifunctionality and Possible Medical Application of the BPC 157 Peptide โ Literature and Patent Review. Pharmaceuticals (Basel). 2025. |
| Systematic review โ orthopaedic sports medicinePreclinical ยท Systematic review | Studies reviewed were preclinical | No human dose identified by the review | Varies by model | โ | โ | Musculoskeletal healing | Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025. |
Where sources disagree
- Vendor documentation, peptide reference sites and earlier versions of this profile commonly publish 250โ500 mcg subcutaneously, once to three times daily. No published human study reports that dose, that route or that frequency for BPC-157, and no primary source for the figure could be identified.
- The only registered trial that discloses a dose used 1โ6 mg by mouth, not micrograms by injection. Oral and subcutaneous dosing are not interchangeable, and that trial has published no results and is listed with unknown status.
- BPC-157 is frequently described as "well tolerated" in secondary sources. No completed human trial has published safety results, so there is no human tolerability evidence to support that description.
Reconstitution
Common research vial sizes: 5 mg, 10 mg.
| Vial | Bacteriostatic water | Concentration | Per 0.01 mL |
|---|---|---|---|
| 5 mg | 2 mL | 2.5 mg/mL | 25 mcg per 0.01 mL |
| 10 mg | 2 mL | 5 mg/mL | 50 mcg per 0.01 mL |
These figures are arithmetic only โ they convert a vial and a volume into a concentration. They are not a recommendation to take any dose.
Calculate reconstitution & dose โHandling & administration
- Reconstitution Guide
- 3 mL BAC water for 5 mg vial
- Injection Sites
- AbdomenThighNear injury
- Concentration Example
- 5 mg / 3 mL = ~1.67 mg/mL
- Timing Notes
- Morning, midday, and evening
- Expected Onset
- 3-7 days
How to reconstitute BPC-157
- Check the vial size and diluent volume. The profile example for BPC-157 is: 3 mL BAC water for 5 mg vial.
- Swab both vial stoppers and draw the bacteriostatic water into a sterile syringe.
- Add the water slowly down the inside wall of the peptide vial so it does not jet onto the powder, then swirl gently until the solution is clear. Do not shake.
- Record the resulting concentration: 5 mg / 3 mL = ~1.67 mg/mL.
- Label the vial with the date and concentration, refrigerate it (see Storage & stability below), and use the calculator preset to convert a dose in mcg into syringe units.
Sequence & molecular data
| Amino acid sequence | Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val |
|---|---|
| Molecular formula | C62H98N16O22 |
| Molecular weight | 1419.5 g/mol |
| CAS number | 137525-51-0 |
| Half-life | ~30 minutes to 4 hours |
| Appearance | White lyophilized powder |
| Formulation | Lyophilized Powder |
| PubChem CID | 9941957 |
| FDA UNII | 8ED8NXK95P |
| ChEMBL | CHEMBL4297358 |
| DrugBank | DB11882 |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
Preclinical work reports angiogenesis, nitric-oxide modulation, and growth-factor (VEGFR2, FAK) signaling that may support tendon, muscle, and gut mucosal healing in animals. Robust randomized human efficacy data are lacking.
Origin
Partial sequence of human gastric juice protein BPC.
Targets
Studies
- Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review
- Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review
- Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing
- Stable Gastric Pentadecapeptide BPC 157 and Intestinal Anastomoses Therapy in Rats-A Review
- Pentadecapeptide BPC 157 and the central nervous system
Regulatory & research status
BPC-157 is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.
| FDA status | Not Approved |
|---|---|
| Availability | Research-Only |
| WADA (sport) | Banned in Sport |
| Library classification | Research-Only |
Benefits
BPC-157 side effects
BPC-157 has no controlled human safety data. The effects below are reported, not established, and absence from the list is not evidence of safety.
Side Effects
- Injection site irritation
- Nausea (rare)
- Fatigue (rare)
Contraindications
- Active cancer
- Pregnancy
Stacking
Common stacking partners
Combinations that include BPC-157, with the proposed rationale, an evidence grade and what is not established, are catalogued in the peptide stacks directory.
Storage & stability
Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.
Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freezeโthaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.
Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.
Read the full guide: how to store peptides before and after reconstitution โ
Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544โ575. (PMID 20143256). General guidance for research handling; not product-specific instructions.
BPC-157: frequently asked questions
What is BPC-157?
Synthetic gastric pentadecapeptide widely sold as a research chemical for tissue-repair models. Not FDA-approved; FDA has flagged it for compounding risk. WADA prohibits BPC-157 under S0. Preclinical work reports angiogenesis, nitric-oxide modulation, and growth-factor (VEGFR2, FAK) signaling that may support tendon, muscle, and gut mucosal healing in animals. Robust randomized human efficacy data are lacking.
What are the side effects of BPC-157?
BPC-157 has no controlled human safety data, so its side-effect profile is not well established. Effects recorded on this profile include injection site irritation, nausea (rare) and fatigue (rare). Cautions recorded on this profile: active cancer and pregnancy. It is on the WADA Prohibited List for athletes. This is reference information, not medical advice.
How does BPC-157 work?
Preclinical work reports angiogenesis, nitric-oxide modulation, and growth-factor (VEGFR2, FAK) signaling that may support tendon, muscle, and gut mucosal healing in animals. Robust randomized human efficacy data are lacking.
Is BPC-157 FDA approved?
No. BPC-157 is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.
What is the half-life of BPC-157?
Reported half-life for BPC-157 is ~30 minutes to 4 hours. Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.
What is the amino acid sequence of BPC-157?
BPC-157 has the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, giving a chain of 15 amino acids. Its molecular formula is C62H98N16O22.
Is BPC-157 banned in sport?
BPC-157 is recorded here as prohibited in sport. Athletes subject to anti-doping rules should check the current WADA Prohibited List directly, since it is revised annually and classifications change.
How long does BPC-157 take to show effects in research protocols?
The research protocol on this profile lists an expected onset of 3-7 days. This is a protocol note describing when studies and researchers report observing changes, not a measured clinical outcome, and it varies with the model, dose and endpoint studied.
Where is BPC-157 administered in research protocols?
Research protocols on this profile use subcutaneous administration, with recorded sites including abdomen, thigh, near injury. Site rotation and sterile technique are standard practice in the research literature; this describes protocol conditions and is not guidance for use.
References
- USADA โ BPC-157 prohibited (S0)External reference
- WADA Prohibited List 2026External reference
- Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review โ Pharmaceuticals (Basel), 2025External reference
- Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review โ HSS J, 2025External reference
- Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing โ Curr Rev Musculoskelet Med, 2025External reference
- Stable Gastric Pentadecapeptide BPC 157 and Intestinal Anastomoses Therapy in Rats-A Review โ Pharmaceuticals (Basel), 2024External reference
- Pentadecapeptide BPC 157 and the central nervous system โ Neural Regen Res, 2022External reference
Related research, comparisons & guides
- BPC-157 Dosage: What the Research Literature Actually Reports
- GLOW Peptide Blend: What Is Actually in the Vial
- KLOW vs GLOW: What Adding KPV Changes, and What It Does Not
- TB-500 Dosage: What the Fragment Is, and What the Numbers Rest On
- Bacteriostatic Water (BAC Water): What It Is, Uses & How Much to Add
- Peptides for Gut Health: Where Local Action Actually Makes Sense
- The Wolverine Stack: What It Is and Where the Name Came From
- BPC-157 Benefits: Sorting the Claims From the Evidence
- BPC-157 Side Effects: The Honest Answer Is That Nobody Has Looked
- Peptide Supplements: What Is Actually in the Bottle
- SARMs vs Peptides: Different Molecules, Different Risks
- Peptide vs Protein: Where the Line Is Drawn
- BPC-157 Capsules: Does Oral BPC-157 Survive Digestion?
- KLOW Peptide Blend: GLOW Plus KPV, and What That Addition Changes
- BPC-157 and TB-500: Why Blended Vials Break the Usual Math
- TB-500
- Muscle and recovery peptidesCategory
- Peptide stacks: combinations by research goalStacks
- Peptide dosage chart: dose, route and frequencyCategory
- BPC-157 calculator: reconstitution and syringe units
- How to store peptides before and after reconstitution
Related peptides
Compiled by Peptide Library Editorial ยท Reviewed Aug 30, 2026 ยท Updated Sep 26, 2026 ยท Version 5
This BPC-157 profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy ยท How profiles are compiled ยท Report an error
Track BPC-157 research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android โ